Literature DB >> 22112758

Synthesis and evaluation of the substrate activity of C-6 substituted purine ribosides with E. coli purine nucleoside phosphorylase: palladium mediated cross-coupling of organozinc halides with 6-chloropurine nucleosides.

Abdalla E A Hassan1, Reham A I Abou-Elkhair, James M Riordan, Paula W Allan, William B Parker, Rashmi Khare, William R Waud, John A Montgomery, John A Secrist.   

Abstract

A series of C-6 alkyl, cycloalkyl, and aryl-9-(β-d-ribofuranosyl)purines were synthesized and their substrate activities with Escherichia coli purine nucleoside phosphorylase (E. coli PNP) were evaluated. (Ph(3)P)(4)Pd-mediated cross-coupling reactions of 6-chloro-9-(2,3,5-tri-O-acetyl-β-d-ribofuranosyl)-purine (6) with primary alkyl (Me, Et, n-Pr, n-Bu, isoBu) zinc halides followed by treatment with NH(3)/MeOH gave the corresponding 6-alkyl-9-(β-d-ribofuranosyl)purine derivatives 7-11, respectively, in good yields. Reactions of 6 with cycloalkyl(propyl, butyl, pentyl)zinc halides and aryl (phenyl, 2-thienyl)zinc halides gave under similar conditions the corresponding 6-cyclopropyl, cyclobutyl, cyclopentyl, phenyl, and thienyl -9-(β-d-ribofuranosyl)purine derivatives 12-16, respectively in high yields. E. coli PNP showed a high tolerance to the steric and hydrophobic environment at the 6-position of the synthesized purine ribonucleosides. Significant cytotoxic activity was observed for 8, 12, 15, and 16. Evaluation of 12 and 16 against human tumor xenografts in mice did not demonstrate any selective antitumor activity. In addition, 6-methyl-9-(β-d-arabinofuranosyl)purine (18) was prepared and evaluated.
Copyright © 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22112758      PMCID: PMC3259247          DOI: 10.1016/j.ejmech.2011.10.039

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  19 in total

1.  In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylase.

Authors:  W B Parker; S A King; P W Allan; L L Bennett; J A Secrist; J A Montgomery; K S Gilbert; W R Waud; A H Wells; G Y Gillespie; E J Sorscher
Journal:  Hum Gene Ther       Date:  1997-09-20       Impact factor: 5.695

2.  Convenient syntheses of 6-methylpurine and related nucleosides.

Authors:  A E Hassan; R A Abou-Elkair; J A Montgomery; J A Secrist
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2000-07       Impact factor: 1.381

3.  Purine nucleoside phosphorylase. 2. Catalytic mechanism.

Authors:  M D Erion; J D Stoeckler; W C Guida; R L Walter; S E Ealick
Journal:  Biochemistry       Date:  1997-09-30       Impact factor: 3.162

4.  Synthesis and antimycobacterial activity of 6-arylpurines: the requirements for the N-9 substituent in active antimycobacterial purines.

Authors:  Lise-Lotte Gundersen; Jon Nissen-Meyer; Bjørn Spilsberg
Journal:  J Med Chem       Date:  2002-03-14       Impact factor: 7.446

5.  Analogs of 6-methyl-9-beta-D-ribofuranosylpurine.

Authors:  J A Montgomery; K Hewson
Journal:  J Med Chem       Date:  1968-01       Impact factor: 7.446

6.  Cytostatic 6-arylpurine nucleosides. 6. SAR in anti-HCV and cytostatic activity of extended series of 6-hetarylpurine ribonucleosides.

Authors:  Michal Hocek; Petr Naus; Radek Pohl; Ivan Votruba; Phillip A Furman; Phillip M Tharnish; Michael J Otto
Journal:  J Med Chem       Date:  2005-09-08       Impact factor: 7.446

7.  Cell to cell contact is not required for bystander cell killing by Escherichia coli purine nucleoside phosphorylase.

Authors:  B W Hughes; S A King; P W Allan; W B Parker; E J Sorscher
Journal:  J Biol Chem       Date:  1998-01-23       Impact factor: 5.157

8.  Synthesis, biotransformation, and pharmacokinetic studies of 9-(beta-D-arabinofuranosyl)-6-azidopurine: a prodrug for ara-A designed to utilize the azide reduction pathway.

Authors:  L P Kotra; K K Manouilov; E Cretton-Scott; J P Sommadossi; F D Boudinot; R F Schinazi; C K Chu
Journal:  J Med Chem       Date:  1996-12-20       Impact factor: 7.446

9.  Synthesis of substituted 6-cyclopropylpurine bases and nucleosides by cross-coupling reactions or cyclopropanations.

Authors:  Martin Kuchar; Radek Pohl; Blanka Klepetárová; Ivan Votruba; Michal Hocek
Journal:  Org Biomol Chem       Date:  2008-05-02       Impact factor: 3.876

10.  Synthesis and structure-activity relationships of 6-heterocyclic-substituted purines as inactivation modifiers of cardiac sodium channels.

Authors:  K G Estep; K A Josef; E R Bacon; P M Carabateas; S Rumney; G M Pilling; D S Krafte; W A Volberg; K Dillon; N Dugrenier
Journal:  J Med Chem       Date:  1995-07-07       Impact factor: 7.446

View more
  4 in total

1.  Use of E. coli Purine Nucleoside Phosphorylase in the Treatment of Solid Tumors.

Authors:  William B Parker; Eric J Sorscher
Journal:  Curr Pharm Des       Date:  2017-11-08       Impact factor: 3.116

2.  Synthesis of C6-Substituted Purine Nucleoside Analogues via Late-Stage Photoredox/Nickel Dual Catalytic Cross-Coupling.

Authors:  James J Perkins; Valerie W Shurtleff; Alayna M Johnson; Abdellatif El Marrouni
Journal:  ACS Med Chem Lett       Date:  2021-03-08       Impact factor: 4.345

3.  Purine (N)-Methanocarba Nucleoside Derivatives Lacking an Exocyclic Amine as Selective A3 Adenosine Receptor Agonists.

Authors:  Dilip K Tosh; Antonella Ciancetta; Eugene Warnick; Robert O'Connor; Zhoumou Chen; Elizabeth Gizewski; Steven Crane; Zhan-Guo Gao; John A Auchampach; Daniela Salvemini; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2016-02-18       Impact factor: 7.446

4.  Direct heterobenzylic fluorination, difluorination and trifluoromethylthiolation with dibenzenesulfonamide derivatives.

Authors:  Michael Meanwell; Bharani Shashank Adluri; Zheliang Yuan; Josiah Newton; Philippe Prevost; Matthew B Nodwell; Chadron M Friesen; Paul Schaffer; Rainer E Martin; Robert Britton
Journal:  Chem Sci       Date:  2018-06-07       Impact factor: 9.825

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.